A detailed history of Vanguard Group Inc transactions in Zomedica Corp. stock. As of the latest transaction made, Vanguard Group Inc holds 48,326,991 shares of ZOM stock, worth $5.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,326,991
Previous 48,326,991 -0.0%
Holding current value
$5.8 Million
Previous $7.25 Million 6.68%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$0.12 - $0.19 $69,199 - $109,565
-576,660 Reduced 1.18%
48,326,991 $7.25 Million
Q4 2023

Mar 11, 2024

BUY
$0.15 - $0.22 $9 - $13
62 Added 0.0%
48,903,651 $9.78 Million
Q4 2023

Feb 14, 2024

BUY
$0.15 - $0.22 $14,340 - $21,032
95,600 Added 0.2%
48,903,589 $9.78 Million
Q2 2023

Aug 14, 2023

SELL
$0.19 - $0.22 $34,121 - $39,508
-179,586 Reduced 0.37%
48,807,989 $9.76 Million
Q1 2023

May 15, 2023

BUY
$0.16 - $0.29 $26,768 - $48,518
167,305 Added 0.34%
48,987,575 $10.3 Million
Q4 2022

Feb 10, 2023

BUY
$0.16 - $0.25 $398,602 - $622,816
2,491,265 Added 5.38%
48,820,270 $7.81 Million
Q3 2022

Nov 14, 2022

BUY
$0.2 - $0.38 $450,530 - $856,007
2,252,651 Added 5.11%
46,329,005 $9.78 Million
Q2 2022

Aug 12, 2022

BUY
$0.2 - $0.34 $693,842 - $1.18 Million
3,469,211 Added 8.54%
44,076,354 $9.7 Million
Q1 2022

May 13, 2022

SELL
$0.28 - $0.4 $287,990 - $411,415
-1,028,539 Reduced 2.47%
40,607,143 $13.7 Million
Q4 2021

Feb 14, 2022

BUY
$0.31 - $0.58 $56,220 - $105,187
181,358 Added 0.44%
41,635,682 $12.8 Million
Q3 2021

Nov 12, 2021

SELL
$0.46 - $0.81 $481,581 - $848,002
-1,046,917 Reduced 2.46%
41,454,324 $21.7 Million
Q2 2021

Aug 13, 2021

BUY
$0.72 - $1.46 $30.6 Million - $62.1 Million
42,501,241 New
42,501,241 $35.4 Million

Others Institutions Holding ZOM

About Zomedica Corp.


  • Ticker ZOM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 979,950,016
  • Market Cap $118M
  • Description
  • Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment...
More about ZOM
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.